@prefix dc1: <http://purl.org/dc/terms/> .
@prefix this: <http://purl.org/np/RAhjWiKNT3Mt-gbw-nRdwMpy6C5dM21O2dcnR1ZTInSvA> .
@prefix sub: <http://purl.org/np/RAhjWiKNT3Mt-gbw-nRdwMpy6C5dM21O2dcnR1ZTInSvA#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_14654> bl:category bl:Disease .
  
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_14654>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/drugbank:DB00567>;
    a rdf:Statement;
    rdfs:label "cephalexin is a cephalosporin antibacterial drug indicated for the treatment of the following infections caused by susceptible isolates of designated bacteria respiratory tract infection 1 1 otitis media 1 2 skin and skin structure infections 1 3 bone infections 1 4 genitourinary tract infections 1 5 to reduce the development of drug resistant bacteria and maintain the effectiveness of cephalexin capsules cephalexin for oral suspension and cephalexin tablets and other antibacterial drugs cephalexin capsules cephalexin for oral suspension and cephalexin tablets should be used only to treat infections that are proven or strongly suspected to be caused by bacteria 1 6 cephalexin is indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae streptococcus pyogenes cephalexin is indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae haemophilus influenzae staphylococcus aureus streptococcus pyogenes moraxella catarrhalis cephalexin is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram positive bacteria staphylococcus aureus streptococcus pyogenes cephalexin is indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus proteus mirabilis cephalexin is indicated for the treatment of genitourinary tract infections including acute prostatitis caused by susceptible isolates of escherichia coli proteus mirabilis klebsiella pneumoniae to reduce the development of drug resistant bacteria and maintain the effectiveness of cephalexin capsules cephalexin for oral suspension and cephalexin tablets and other antibacterial drugs cephalexin capsules cephalexin for oral suspension and cephalexin tablets should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information is available this information should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy";
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:relation schema:TreatmentIndication .
  
  <https://identifiers.org/drugbank:DB00567> bl:category bl:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "BcTRu5VM9adT5/mHKquzCS6sBBa0uOtDI0Wv5nleAPRXKQtPDrLsg5A4BUWKUhHMjAqhnweHAAp3JC+/78+LPZe5daB/3Qtp6ZMqgawQQdKXjiMluMAyqukYzIsSQHzVYAbeUTI7bSJgyIJs741zBy46xWl3EC1kzV/6UF6mt4A=";
    npx:hasSignatureTarget this: .
  
  this: dc1:created "2021-06-13T15:56:39.798+02:00"^^xsd:dateTime;
    dc1:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}